None

On Friday, 61 companies hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: Ecopetrol (NYSE:EC) was the biggest company in terms of market cap to set a new 52-week low. ThermoGenesis Holdings (NASDAQ:THMO) was the smallest company in terms of market cap to set a new 52-week low. Quotient (NASDAQ:QTNT)'s stock dropped the most, trading down 31.75% to reach a new 52-week low. Natures Sunshine Products (NASDAQ:NATR)'s stock bounced back the most, actually rising 0.09% after reaching its new 52-week low. The following stocks achieved new 52-week lows on Friday: Ecopetrol (NYSE:EC) shares moved up 3.56% on Friday to hit a new 52-week low of $10.78, drifting up 3.56%. Inter & Co (NASDAQ:INTR) shares reached a new 52-week low of $3.08 on Friday morning, moving down 5.4%. Kinross Gold (NYSE:KGC) shares hit a yearly low of $3.83. The stock was down 0.38% on the session. Grupo Aval Acciones (NYSE:AVAL) shares set a new 52-week low of $3.55. The stock traded up 2.22%. Alvotech (NASDAQ:ALVO) shares made a new 52-week low of $8.67 on Friday. The stock was up 1.89% for the day. Seabridge Gold (NYSE:SA) shares moved up 2.24% on Friday to hit a new 52-week low of $12.75, drifting up 2.24%. Schnitzer Steel Indus (NASDAQ:SCHN) shares moved up 2.33% on Friday to hit a new 52-week low of $32.16, drifting up 2.33%. Companhia Brasileira (NYSE:CBD) stock achieved a new 52-week low on Friday morning, hitting $3.09 and moving down 1.1%. New Found Gold (AMEX:NFGC) stock achieved a new 52-week low on Friday morning, hitting $4.68 and moving up 1.01%. First Mid Bancshares (NASDAQ:FMBH) stock set a new 52-week low of $35.05 on Friday, moving up 0.76%. Liberty TripAdvisor Hldgs (NASDAQ:LTRPB) stock dropped to a yearly low on Friday of $8.49. Shares traded up 8.4%. Skillsoft (NYSE:SKIL) stock achieved a new 52-week low on Friday morning, hitting $4.10 and moving down 7.65%. Vtex (NYSE:VTEX) stock achieved a new 52-week low on Friday morning, hitting $3.56 and moving down 2.19%. Denny's (NASDAQ:DENN) shares fell to $8.46 on Friday, setting a new 52-week low with a shift of up 2.7%. Cementos Pacasmayo (NYSE:CPAC) shares reached a new 52-week low of $4.72 on ...

Related tickers: OPRT, NYC, RICO, NATR, THMO, PW, VINE, CPAC, ATCX, SA, WULF, FMBH, IPDN, INVO, CBAN, ADTH, BIOC, UPC, CRTX, PRDS, QTNT, OTMO, DENN, GRNA, RYAM, LVOX, DWSN, LCFY, AVAL, NLIT, KTCC, ALVO, INTR, VTEX, MTEX, LTRPB, LRFC, SCHN, VRME, VEV, SKIL, AVYA, AUID, CBD, ABVC, DOMA, EC, ACHV, NFGC, GF, HUGE, LYLT, GLS, IPX, VAXX, KGC.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer Acquires Biohaven For $11B Pfizer Inc (NYSE: PFE) will acquire Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) for $148.50 per share, equivalent to $11.6 billion.  The deal includes the acquisition of rimegepant (NURTEC ODT), a dual-acting migraine therapy approved for acute treatment and episodic prevention of migraine in adults, Zavegepant, and a portfolio of five preclinical CGRP assets. BHVN shares are up 74.4% at $144.98 during the premarket session. Praxis' PRAX-944 Shows Promising Action In Essential Tremor Patients Praxis Precision Medicines Inc (NASDAQ: PRAX) announced topline results from Part B of its Phase 2a study evaluating the safety and efficacy of PRAX-944 for essential tremors.  Treatment with PRAX-944 resulted in clinically meaningful improvements in function, supported by improvements in tremor amplitude. PRAX-944 was generally well tolerated in Part B of the Phase 2a study, with no new safety findings. Eisai, Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug Eisai Co Ltd (OTC: ESALY) has completed the rolling submission of the FDA marketing application under the accelerated approval for lecanemab (BAN2401) for mild cognitive impairment due to Alzheimer's disease (AD) and mild AD. Eisai is collaborating with Biogen Inc (NASDAQ: BIIB) for drug development. Eisai has requested a Priority Review, while the lecanemab Phase 3 Clarity AD trial conducted with 1,795 patients will report out in the fall of 2022.  Arcus Posts Encouraging Data For Domvanalimab-Based Regimes In Lung Cancer Settings Arcus Biosciences Inc (NYSE: RCUS) announced results from the third interim analysis of the ongoing Phase 2 ARC-7 study of zimberelimab vs. domvanalimab plus zimberelimab (doublet) vs. domvanalimab plus zimberelimab and etrumadenant (triplet) as a first-line treatment for metastatic non-small cell lung cancer. In this interim analysis, both domvanalimab-containing arms continued to show meaningful differentiation compared to zimberelimab alone across multiple efficacy measures, including overall response rate and duration of response.  Longeveron CEO Steps Down Longeveron Inc (NASDAQ:

Related tickers: GMDA, AGEN, RVNC, IMUX, ARWR, ITCI, IMTX, BIIB, CALA, PRAX, CGEN, XENE, EVAX, CPRX, AVGR, LGVN, CRTX, RETA, VERV, EXEL, AVIR, IBB, MYOV, OPNT, URGN, BMY, BHVN, PFE, ATNX, SYN, VERU, ZEAL, CERE, ZLAB, RCUS, RUBY.